NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice.
Ontology highlight
ABSTRACT: The causal association of Zika virus (ZIKV) with microcephaly, congenital malformations in infants, and Guillain-Barré syndrome in adults highlights the need for effective vaccines. Thus far, efforts to develop ZIKV vaccines have focused on the viral envelope. ZIKV NS1 as a vaccine immunogen has not been fully explored, although it can circumvent the risk of antibody-dependent enhancement of ZIKV infection, associated with envelope antibodies. Here, we describe a novel DNA vaccine encoding a secreted ZIKV NS1, that confers rapid protection from systemic ZIKV infection in immunocompetent mice. We identify novel NS1 T cell epitopes in vivo and show that functional NS1-specific T cell responses are critical for protection against ZIKV infection. We demonstrate that vaccine-induced anti-NS1 an
SUBMITTER: Grubor-Bauk B
PROVIDER: S-EPMC6905874 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA